Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX(TM) for the Treatment of Dupuytren's Contracture

For More Information:

James E. Fickenscher

Chief Financial Officer

Auxilium Pharmaceuticals, Inc.

1-484-321-5900

[email protected]

William Q. Sargent Jr.

Vice-President

Investor Relations and Corporate Communications

1-484-321-5900

[email protected]